Home / Current Affairs / Coronavirus / News / WHO to end anti-malaria drug hydroxycholorquine trial for coronavirus cure

WHO to end anti-malaria drug hydroxycholorquine trial for coronavirus cure

WHO said Saturday it has 'accepted the recommendation' from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab

Premium

WHO says the decision won't affect possible trials on patients who aren't hospitalized

AP | PTI

1 min read Last Updated : Jul 06 2020 | 2:39 AM IST

The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalised with Covid-19.

WHO said Saturday it has “accepted the recommendation” from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir “produce little or no reduction in the mortality of hospitalised Covid-19 patients when compared to standard of care.” The agency adds that while there was no “solid evidence” of increased mortality

Topics : Coronavirus Vaccine COVID-19

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in